Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.69 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | FER | P16591 | 1/20 | 0.69 |
| ▸ | LTK | P29376 | 1/20 | 0.69 |
| ▸ | CDK8 | P49336 | 1/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.69 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.66 |
| ▸ | CES1 | P23141 | 2/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | ROS1 | P08922 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368761 | 1.00 | CHEK1 (1.00) | CHEK1LRRK2ACVR1PDGFRAFER | |
| SCHEMBL29532517 | 1.00 | CHEK1 (1.00) | CHEK1LRRK2ACVR1PDGFRAFER | |
| SCHEMBL3614440 | 0.89 | CHEK1 (0.81) | CHEK1LRRK2ACVR1PDGFRAFER | |
| SCHEMBL29485956 | 0.89 | CHEK1 (0.81) | CHEK1LRRK2ACVR1PDGFRAFER | |
| SCHEMBL4856816 | 0.89 | CHEK1 (0.81) | CHEK1LRRK2ACVR1PDGFRAFER | |
| SCHEMBL8204226 | 0.84 | CHEK1 (0.72) | CHEK1LRRK2ACVR1PDGFRAFER | |
| SCHEMBL13826690 | 0.83 | CHEK1 (0.69) | CHEK1LRRK2CSNK1G1CES1TGM2 | |
| SCHEMBL1368292 | 0.83 | LRRK2 (1.00) | CHEK1LRRK2ACVR1PDGFRAFER | |
| Hydrochloric Acid SCHEMBL6299954 | 0.81 | LRRK2 (0.95) | CHEK1LRRK2ACVR1PDGFRAFER | |
| SCHEMBL3411665 | 0.80 | CHEK1 (0.67) | CHEK1LRRK2ACVR1PDGFRAFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | IFOM —FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2025-09-02 | — | — | US | disclosed |
| EP-3976185-B1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2024-02-14 | — | — | EP | disclosed |
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-10-27 | — | — | US | disclosed |
| EP-3976185-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020245213-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020245213-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2020-12-10 | — | — | WO | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| WO-2009137499-A1 | INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| US-3956297-A | 9H-Dibenzo[b,f]imidazo[1,2-d][1,4]diazepines | THE UPJOHN COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | NEDD4, ITCH, UBE3A | CHEK1 1414/4885LRRK2 184/4885ACVR1 2925/4885 |
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | NEDD4, ITCH, UBE3A | CHEK1 1414/4885LRRK2 184/4885ACVR1 2925/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | CHEK1 2086/4885LRRK2 4103/4885ACVR1 2607/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | CHEK1 1614/4885LRRK2 1758/4885ACVR1 4646/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | CHEK1 2719/4885LRRK2 4389/4885ACVR1 3411/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | CHEK1 2086/4885LRRK2 4103/4885ACVR1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.